Findings of Research Misconduct, 44627-44628 [2019-18305]
Download as PDF
<![CDATA[
44627
Federal Register / Vol. 84, No. 165 / Monday, August 26, 2019 / Notices
Information Collection Clearance
Officer, Room 14N136B, 5600 Fishers
Lane, Rockville, Maryland 20857.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the data collection plans and draft
instruments, email paperwork@hrsa.gov
or call Lisa Wright-Solomon, the HRSA
Information Collection Clearance Officer
at (301) 443–1984.
SUPPLEMENTARY INFORMATION: When
submitting comments or requesting
information, please include the ICR title
for reference.
Information Collection Request Title:
Rural Health Network Development
Planning Performance Improvement and
Measurement System Database, OMB
No. 0915–0384—Extension.
Abstract: The purpose of the Rural
Health Network Development Planning
(Network Planning) Program is to assist
in the development of an integrated
health care network specifically for
entities that do not have a history of
formal collaborative efforts. Health care
networks can be an effective strategy to
help smaller rural health care providers
and health care service organizations
align resources, achieve economies of
scale and efficiency, and address
challenges more effectively as a group
than as single providers. This program
promotes the planning and development
of healthcare networks in order to
achieve efficiencies; expand access to,
coordinate, and improve the quality of
essential health care services; and
strengthen the rural health care system
as a whole.
The goals of the Network Planning
Program are centered around
approaches that will aid providers in
better serving their communities given
the changes taking place in health care,
as providers move from focusing on the
volume of services to focusing on the
value of services. In addition to
establishing and improving local
capacity and coordination of care, the
Network Planning Program brings
together key parts of a rural health care
delivery system, particularly those
entities that may not have collaborated
in the past under a formal relationship.
The program supports one year of
planning with the primary goals of
helping networks create a foundation for
their infrastructure and focusing
member efforts to address important
regional or local community health
needs.
Need and Proposed Use of the
Information: Performance measures for
the Network Planning Program serve the
purpose of quantifying awardee-level
data that conveys the successes and
challenges associated with the grant
award. These measures and aggregate
data substantiate and inform the focus
and objectives of the grant program. The
approved measures encompass the
following principal topic areas: Network
infrastructure, network collaboration,
sustainability, and network assessment.
Likely Respondents: Rural Health
Network Development Planning
Program award recipients.
Burden Statement: Burden in this
context means the time expended by
persons to generate, maintain, retain,
disclose or provide the information
requested. This includes the time
needed to review instructions; to
develop, acquire, install, and utilize
technology and systems for the purpose
of collecting, validating, and verifying
information, processing and
maintaining information, and disclosing
and providing information; to train
personnel and to be able to respond to
a collection of information; to search
data sources; to complete and review
the collection of information; and to
transmit or otherwise disclose the
information. The total annual burden
hours estimated for this ICR are
summarized in the table below.
TOTAL ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Form name
Total
responses
Average
burden per
response
(in hours)
Total burden
hours
Rural Health Network Development Planning Program
Performance Improvement Measurement System ..........
21
1
21
1
21
Total ..............................................................................
21
........................
21
........................
21
HRSA specifically requests comments
on (1) the necessity and utility of the
proposed information collection for the
proper performance of the agency’s
functions, (2) the accuracy of the
estimated burden, (3) ways to enhance
the quality, utility, and clarity of the
information to be collected, and (4) the
use of automated collection techniques
or other forms of information
technology to minimize the information
collection burden.
khammond on DSKBBV9HB2PROD with NOTICES
Number of
responses per
respondent
Maria G. Button,
Director, Division of the Executive Secretariat.
[FR Doc. 2019–18331 Filed 8–23–19; 8:45 am]
BILLING CODE 4165–15–P
VerDate Sep<11>2014
16:09 Aug 23, 2019
Jkt 247001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
Findings of research
misconduct have been made against Dr.
Rahul Agrawal (Respondent), former
visiting fellow at the Center for Cancer
Research, Laboratory of Pathology,
Cancer Molecular Pathology Section,
National Cancer Institute (NCI),
National Institutes of Health (NIH). Dr.
Agrawal engaged in research
misconduct in research supported by
the Intramural Research Program of NCI,
NIH. The administrative actions,
including supervision for a period of
SUMMARY:
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
one (1) year, were implemented
beginning on August 8, 2019, and are
detailed below.
FOR FURTHER INFORMATION CONTACT:
Wanda K. Jones, Dr.P.H., Acting
Director, Deputy Director, Office of
Research Integrity, 1101 Wootton
Parkway, Suite 750, Rockville, MD
20852, (240) 453–8200.
SUPPLEMENTARY INFORMATION: Notice is
hereby given that the Office of Research
Integrity (ORI) has taken final action in
the following case:
Dr. Rahul Agrawal, National Institutes
of Health: Based on Respondent’s
admission, an assessment conducted by
NIH, and additional analysis conducted
by ORI in its oversight review, ORI
found that Dr. Rahul Agrawal, former
visiting fellow at the Center for Cancer
Research, Laboratory of Pathology,
Cancer Molecular Pathology Section,
E:\FR\FM\26AUN1.SGM
26AUN1
khammond on DSKBBV9HB2PROD with NOTICES
44628
Federal Register / Vol. 84, No. 165 / Monday, August 26, 2019 / Notices
NCI, NIH, engaged in research
misconduct in research supported by
the Intramural Research Program of NCI,
NIH.
ORI found that Respondent engaged
in research misconduct by intentionally,
knowingly, and/or recklessly falsifying
and/or fabricating data in the
unpublished research record by the
alteration, reuse, and/or relabeling of
quantitative real-time polymerase chain
reaction (qRT–PCR) data and colony
forming cell (CFC) and focus formation
(FF) assay images to represent
experiments that measured microRNA
expression levels and the effect of long
intergenic non-protein coding (LINC)
RNAs in human cancer cell lines that
were not conducted.
Specifically, ORI found that
Respondent knowingly, intentionally,
and/or recklessly falsified and/or
fabricated:
• qRT–PCR data in fifty-nine (59) Excel
files by:
—Conceiving Cycle Threshold (CT)
values and PCR machine run
identification numbers and run dates
for fifty-nine (59) experiments that
were not conducted
—inserting falsified and/or fabricated
CT values in fifty-four (54) files that
originated from one (1) Excel template
with a single file creation date to
represent distinct experimental runs
with different experimental dates in
exported Excel files from the PCR
machine
—utilizing an earlier PCR machine
calibration date in four (4) Excel files
to represent experiments completed at
a later date
• CFC and FF assay images in four (4)
PowerPoint files by:
—Representing eight (8) images of CFC
and FF assays in cell culture plates as
the overexpression of LINC00379 or
LINC00380 in human alveolar
rhabdomyosarcoma RD and Rh41
cells when the cultured cells did not
overexpress the specific LINC RNA
Dr. Agrawal entered into a Voluntary
Settlement Agreement (Agreement) and
voluntarily agreed:
(1) To have his research supervised
for a period of one (1) year beginning on
August 8, 2019; Respondent agreed that
prior to the submission of an
application for U.S. Public Health
Service (PHS) support for a research
project on which Respondent’s
participation is proposed and prior to
Respondent’s participation in any
capacity on PHS-supported research,
Respondent shall ensure that a plan for
supervision of Respondent’s duties is
submitted to ORI for approval; the
supervision plan must be designed to
VerDate Sep<11>2014
16:09 Aug 23, 2019
Jkt 247001
ensure the scientific integrity of
Respondent’s research contribution;
Respondent agreed that he shall not
participate in any PHS-supported
research until such a supervision plan is
submitted to and approved by ORI;
Respondent agreed to maintain
responsibility for compliance with the
agreed upon supervision plan;
(2) that the requirements for
Respondent’s supervision plan are as
follows:
i. A committee of 2–3 senior faculty
members at the institution who are
familiar with Respondent’s field of
research, but not including
Respondent’s supervisor or
collaborators, will provide oversight and
guidance for one (1) year beginning on
August 8, 2019; the committee will
review primary data from Respondent’s
laboratory on a quarterly basis and
submit a report to ORI at six (6) month
intervals setting forth the committee
meeting dates, Respondent’s compliance
with appropriate research standards,
and confirming the integrity of
Respondent’s research; and
ii. the committee will conduct an
advance review of any PHS grant
applications (including supplements,
resubmissions, etc.), manuscripts
reporting PHS-funded research
submitted for publication, and abstracts;
the review will include a discussion
with Respondent of the primary data
represented in those documents and
will include a certification to ORI that
the data presented in the proposed
application/publication is supported by
the research record;
(3) that for a period of one (1) year
beginning on August 8, 2019, any
institution employing him shall submit,
in conjunction with each application for
PHS funds, or report, manuscript, or
abstract involving PHS-supported
research in which Respondent is
involved, a certification to ORI that the
data provided by Respondent are based
on actual experiments or are otherwise
legitimately derived and that the data,
procedures, and methodology are
accurately reported in the application,
report, manuscript, or abstract;
(4) that if no supervisory plan is
provided to ORI, Respondent shall
provide certification to ORI at the
conclusion of the supervision period
that he has not engaged in, applied for,
or had his name included on any
application, proposal, or other request
for PHS funds without prior notification
to ORI; and
(5) to exclude himself from serving in
any advisory capacity to PHS including,
but not limited to, service on any PHS
advisory committee, board, and/or peer
review committee, or as a consultant for
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
a period of one (1) year beginning on
August 8, 2019.
Wanda K. Jones,
Acting Director, Deputy Director, Office of
Research Integrity.
[FR Doc. 2019–18305 Filed 8–23–19; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; S10
Programs for Shared Instrumentation Grant
(SIG) and Shared Instrumentation for Animal
Research (SIFAR) Grant.
Date: September 25–26, 2019.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Washington/Rockville, 1750
Rockville Pike, Rockville, MD 20852.
Contact Person: Jan Li, MD, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5106,
Bethesda, MD 20892, 301.402.9607, Jan.Li@
nih.gov.
Name of Committee: Oncology 2—
Translational Clinical Integrated Review
Group Cancer Biomarkers Study Section.
Date: September 26–27, 2019.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Courtyard Seattle Pioneer Square,
612 2nd Ave, Seattle, WA 98104.
Contact Person: Lawrence Ka-Yun Ng,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6152,
MSC 7804, Bethesda, MD 20892, 301–357–
9318, ngkl@csr.nih.gov.
Name of Committee: Molecular, Cellular
and Developmental Neuroscience Integrated
Review Group, Neurotransporters, Receptors,
and Calcium Signaling Study Section.
Date: September 26, 2019.
Time: 8:00 a.m. to 8:00 p.m.
E:\FR\FM\26AUN1.SGM
26AUN1
]]>Agencies
[Federal Register Volume 84, Number 165 (Monday, August 26, 2019)]
[Notices]
[Pages 44627-44628]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-18305]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Findings of research misconduct have been made against Dr.
Rahul Agrawal (Respondent), former visiting fellow at the Center for
Cancer Research, Laboratory of Pathology, Cancer Molecular Pathology
Section, National Cancer Institute (NCI), National Institutes of Health
(NIH). Dr. Agrawal engaged in research misconduct in research supported
by the Intramural Research Program of NCI, NIH. The administrative
actions, including supervision for a period of one (1) year, were
implemented beginning on August 8, 2019, and are detailed below.
FOR FURTHER INFORMATION CONTACT: Wanda K. Jones, Dr.P.H., Acting
Director, Deputy Director, Office of Research Integrity, 1101 Wootton
Parkway, Suite 750, Rockville, MD 20852, (240) 453-8200.
SUPPLEMENTARY INFORMATION: Notice is hereby given that the Office of
Research Integrity (ORI) has taken final action in the following case:
Dr. Rahul Agrawal, National Institutes of Health: Based on
Respondent's admission, an assessment conducted by NIH, and additional
analysis conducted by ORI in its oversight review, ORI found that Dr.
Rahul Agrawal, former visiting fellow at the Center for Cancer
Research, Laboratory of Pathology, Cancer Molecular Pathology Section,
[[Page 44628]]
NCI, NIH, engaged in research misconduct in research supported by the
Intramural Research Program of NCI, NIH.
ORI found that Respondent engaged in research misconduct by
intentionally, knowingly, and/or recklessly falsifying and/or
fabricating data in the unpublished research record by the alteration,
reuse, and/or relabeling of quantitative real-time polymerase chain
reaction (qRT-PCR) data and colony forming cell (CFC) and focus
formation (FF) assay images to represent experiments that measured
microRNA expression levels and the effect of long intergenic non-
protein coding (LINC) RNAs in human cancer cell lines that were not
conducted.
Specifically, ORI found that Respondent knowingly, intentionally,
and/or recklessly falsified and/or fabricated:
qRT-PCR data in fifty-nine (59) Excel files by:
--Conceiving Cycle Threshold (CT) values and PCR machine run
identification numbers and run dates for fifty-nine (59) experiments
that were not conducted
--inserting falsified and/or fabricated CT values in fifty-four (54)
files that originated from one (1) Excel template with a single file
creation date to represent distinct experimental runs with different
experimental dates in exported Excel files from the PCR machine
--utilizing an earlier PCR machine calibration date in four (4) Excel
files to represent experiments completed at a later date
CFC and FF assay images in four (4) PowerPoint files by:
--Representing eight (8) images of CFC and FF assays in cell culture
plates as the overexpression of LINC00379 or LINC00380 in human
alveolar rhabdomyosarcoma RD and Rh41 cells when the cultured cells did
not overexpress the specific LINC RNA
Dr. Agrawal entered into a Voluntary Settlement Agreement
(Agreement) and voluntarily agreed:
(1) To have his research supervised for a period of one (1) year
beginning on August 8, 2019; Respondent agreed that prior to the
submission of an application for U.S. Public Health Service (PHS)
support for a research project on which Respondent's participation is
proposed and prior to Respondent's participation in any capacity on
PHS-supported research, Respondent shall ensure that a plan for
supervision of Respondent's duties is submitted to ORI for approval;
the supervision plan must be designed to ensure the scientific
integrity of Respondent's research contribution; Respondent agreed that
he shall not participate in any PHS-supported research until such a
supervision plan is submitted to and approved by ORI; Respondent agreed
to maintain responsibility for compliance with the agreed upon
supervision plan;
(2) that the requirements for Respondent's supervision plan are as
follows:
i. A committee of 2-3 senior faculty members at the institution who
are familiar with Respondent's field of research, but not including
Respondent's supervisor or collaborators, will provide oversight and
guidance for one (1) year beginning on August 8, 2019; the committee
will review primary data from Respondent's laboratory on a quarterly
basis and submit a report to ORI at six (6) month intervals setting
forth the committee meeting dates, Respondent's compliance with
appropriate research standards, and confirming the integrity of
Respondent's research; and
ii. the committee will conduct an advance review of any PHS grant
applications (including supplements, resubmissions, etc.), manuscripts
reporting PHS-funded research submitted for publication, and abstracts;
the review will include a discussion with Respondent of the primary
data represented in those documents and will include a certification to
ORI that the data presented in the proposed application/publication is
supported by the research record;
(3) that for a period of one (1) year beginning on August 8, 2019,
any institution employing him shall submit, in conjunction with each
application for PHS funds, or report, manuscript, or abstract involving
PHS-supported research in which Respondent is involved, a certification
to ORI that the data provided by Respondent are based on actual
experiments or are otherwise legitimately derived and that the data,
procedures, and methodology are accurately reported in the application,
report, manuscript, or abstract;
(4) that if no supervisory plan is provided to ORI, Respondent
shall provide certification to ORI at the conclusion of the supervision
period that he has not engaged in, applied for, or had his name
included on any application, proposal, or other request for PHS funds
without prior notification to ORI; and
(5) to exclude himself from serving in any advisory capacity to PHS
including, but not limited to, service on any PHS advisory committee,
board, and/or peer review committee, or as a consultant for a period of
one (1) year beginning on August 8, 2019.
Wanda K. Jones,
Acting Director, Deputy Director, Office of Research Integrity.
[FR Doc. 2019-18305 Filed 8-23-19; 8:45 am]
BILLING CODE 4150-31-P
